Klenk Christoph, Humrich Jan, Quitterer Ursula, Lohse Martin J
Institute of Pharmacology, University of Würzburg, Versbacher Strasse 9, D-97078 Würzburg, Germany.
J Biol Chem. 2006 Mar 31;281(13):8357-64. doi: 10.1074/jbc.M513703200. Epub 2006 Jan 18.
Phosducin regulates Gbetagamma-stimulated signaling by binding to Gbetagamma subunits of heterotrimeric G-proteins. Control of phosducin activity by phosphorylation is well established. However, little is known about other mechanisms that may control phosducin activity. Here we report that phosducin is regulated at the posttranslational level by modification with the small ubiquitin-related modifier, SUMO. We demonstrate modification with SUMO for phosducin in vitro expressed in cells and for native phosducin purified from retina and the heart. A consensus motif for SUMOylation was identified in phosducin at amino acid positions 32-35. Mutation of the conserved lysine 33 to arginine in this motif abolished SUMOylation of phosducin, indicating that SUMO is attached to lysine 33 of phosducin. In transfected cells the steady-state levels of the K33R mutant protein were much lower compared with wild-type phosducin. The investigation of the stability of wild-type phosducin and of phosducinK33R showed a decreased protein stability of the SUMOylation-deficient mutant. The decreased protein stability correlated with increased ubiquitinylation of the SUMOylation-deficient mutant. These findings indicate that SUMOylation protects phosducin from proteasomal degradation. SUMOylation of phosducin decreased its ability to bind Gbetagamma. PhlP, a closely related member of the phosducin family, was not a target for SUMOylation, but its SUMOylation can be achieved by a single amino acid insertion in the conserved N terminus of PhlP. Together, these findings show that phosducin is a previously unrecognized target of SUMO modification and that SUMOylation controls phosducin stability in cells as well as its functional properties.
磷光蛋白通过与异源三聚体G蛋白的Gβγ亚基结合来调节Gβγ刺激的信号传导。通过磷酸化对磷光蛋白活性的控制已得到充分证实。然而,对于可能控制磷光蛋白活性的其他机制知之甚少。在这里,我们报告磷光蛋白在翻译后水平上通过与小泛素相关修饰物SUMO的修饰而受到调节。我们证明了在细胞中体外表达的磷光蛋白以及从视网膜和心脏纯化的天然磷光蛋白都有SUMO修饰。在磷光蛋白的第32-35位氨基酸处鉴定出一个SUMO化的共有基序。该基序中保守的赖氨酸33突变为精氨酸消除了磷光蛋白的SUMO化,表明SUMO附着在磷光蛋白的赖氨酸33上。在转染细胞中,K33R突变蛋白的稳态水平与野生型磷光蛋白相比要低得多。对野生型磷光蛋白和磷光蛋白K33R稳定性的研究表明,SUMO化缺陷型突变体的蛋白质稳定性降低。蛋白质稳定性的降低与SUMO化缺陷型突变体泛素化的增加相关。这些发现表明SUMO化保护磷光蛋白免受蛋白酶体降解。磷光蛋白的SUMO化降低了其与Gβγ结合的能力。磷光蛋白家族的密切相关成员PhlP不是SUMO化的靶标,但其SUMO化可通过在PhlP保守的N末端插入单个氨基酸来实现。总之,这些发现表明磷光蛋白是SUMO修饰以前未被认识的靶标,并且SUMO化控制细胞中磷光蛋白的稳定性及其功能特性。